# Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

> **NCT03645746** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** REGN5069
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03645746
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03645746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03645746, "Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03645746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*